Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 Deficiency

31. august 2026 oppdatert av: Immedica Pharma AB

An Open-label, Multicentre Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of AEB1102 in Patients With Arginase 1 Deficiency

The purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who complete Study CAEB1102-101A.

Studieoversikt

Status

Fullført

Intervensjon / Behandling

Detaljert beskrivelse

Purpose of this study is to determine the safety, tolerability, and efficacy of long-term intravenous and subcutaneous administration of pegzilarginase for the treatment of pediatric and adult patients with ARG1-D who complete Study CAEB1102-101A.

Studietype

Intervensjonell

Registrering (Faktiske)

14

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Ontario
      • Toronto, Ontario, Canada, M5G 1X8
        • The Hospital for Sick Children
    • California
      • Stanford, California, Forente stater, 94305
        • Stanford University School of Medicine
    • Florida
      • Gainsville, Florida, Forente stater, 32610
        • University of Florida
    • New York
      • New York, New York, Forente stater, 10029
        • Icahn School of Medicine at Mount Sinai
    • Texas
      • Dallas, Texas, Forente stater, 75390
        • UTSW
      • Porto, Portugal
        • Centro Hospitalar S. Joao
      • London, Storbritannia
        • Great Ormond Street Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

2 år og eldre (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Complete treatment in Study CAEB1102-101A without experiencing any clinically significant adverse event or other unmanageable drug toxicity that would preclude continued dosing
  2. Confirmation by the Investigator and the Sponsor determine that it is acceptable for the patient to continue dosing with AEB1102
  3. If female and of child-bearing potential, has a negative serum pregnancy test within 7 days before enrollment
  4. If sexually active (male or female), must be surgically sterile, post-menopausal (female), or must agree to use a physician-approved method of birth control during the study and for a minimum of 30 days after the last study drug administration
  5. Patient or legal guardian is able and willing to provide written informed consent and where required assent, and to comply with all requirements of study participation (including all study procedures and continuation of prescribed diet without modification), prior to any screening procedures

Exclusion Criteria:

1. Clinically significant concurrent disease, serious intercurrent illness, or other extenuating circumstances

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: pegzilarginase (AEB1102)

Each patient may receive pegzilarginase administered IV or SC for up to 4 years.

modified human arginase I

Andre navn:
  • Co-ArgI-PEG
  • Pegzilarginase

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Number of Participants With Treatment-related Adverse Events
Tidsramme: From start of study up to 262 weeks
From start of study up to 262 weeks
Number of Participants With Anti-pegzilarginase and Anti-PEG Antibodies
Tidsramme: From start of study up to 262 weeks
From start of study up to 262 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Plasma Arginine Levels
Tidsramme: From start of study up to 240 weeks

Change in plasma arginine concentrations from study Baseline

From start of study up to 240 weeks
Plasma GC Levels (Argininic Acid)
Tidsramme: From start of study up to 240 weeks

Change in plasma argininic acid concentrations from study Baseline

From start of study up to 240 weeks
Plasma GC Levels (Guanidinoacetic Acid)
Tidsramme: From start of study up to 240 weeks

Change in plasma guanidinoacetic acid concentrations from study Baseline

From start of study up to 240 weeks
Plasma GC Levels (α-keto-δ-guanidinovaleric Acid)
Tidsramme: From start of study up to 240 weeks

Change in plasma α-keto-δ-guanidinovaleric acid concentrations from study Baseline

From start of study up to 240 weeks
Plasma GC Levels (α-N-acetylarginine)
Tidsramme: From start of study up to 240 weeks

Change in plasma α-N-acetylarginine concentrations from study Baseline

From start of study up to 240 weeks
Six-Minute Walk Test (6MWT)
Tidsramme: From start of study up to 262 weeks

Change in 6MWT distance from study Baseline

From start of study up to 262 weeks
Gross Motor Function Measure (GMFM) Part D
Tidsramme: From start of study up to 262 weeks

Change from study Baseline. The GMFM-D evaluates the patient's ability to stand via assessment of 13 activities, each of which is scored on a scale of 0 to 3, with a scale range of 0-39 points. An increase in GMFM-D score indicates improvement in standing.

From start of study up to 262 weeks
Gross Motor Function Measure (GMFM) Part E
Tidsramme: From start of study up to 262 weeks

Change from study Baseline. The GMFM-E evaluates a subject's ability to walk, run, and jump via assessment of 24 activities, each of which is scored on a scale of 0 to 3, , with a scale range of 0-72. A higher GMFM-E score indicates greater ability, with increasing scores indicating improvement in walking, running, and jumping.

From start of study up to 262 weeks
Modified Ashworth Scale (MAS)
Tidsramme: From start of study up to 262 weeks

Spasticity improvement for lower body muscle groups based on MAS from study Baseline. The MAS is used to measure the resistance to passive movement about a joint due to spasticity using a 6-point scoring scale with possible values of 0, 1, 1+ (scored as 1.5), 2, 3, and 4, where 0 is no increase in muscle tone (no spasticity) and 4 is affected part(s) rigid in flexion or extension (total rigidity). Thus, a decrease in MAS score indicates improvement in spasticity.

From start of study up to 262 weeks
Berg Balance Scale (BBS)
Tidsramme: From start of study up to 262 weeks

Change from study Baseline. The BBS, a measure of balance, utilizes a 5-point scoring scale of 0 (indicating the lowest level of function) to 4 (indicating the highest level of function) for 14 tasks, giving a scale range of 0-56, with a higher score representing better balance.

From start of study up to 262 weeks
Purdue Pegboard Test (Dominant Hand)
Tidsramme: From start of study up to 262 weeks

Change from study Baseline. The Purdue Pegboard Test evaluates manipulative dexterity and bimanual coordination, measuring performance speed in a fine motor task via gross movements of the arms, hands, and fingers, as well as fine motor extremity dexterity. A higher Purdue Pegboard Test score indicates better dexterity and coordination. Scores were compared to normative data, compiled from healthy individuals, to produce a Z-score (0 being population mean). A positive Z-score indicates the raw score is higher than the mean average; a negative Z-score indicates the raw score is below the mean average.

From start of study up to 262 weeks
Purdue Pegboard Test (Non-dominant Hand)
Tidsramme: From start of study up to 262 weeks

Change from study Baseline. The Purdue Pegboard Test evaluates manipulative dexterity and bimanual coordination, measuring performance speed in a fine motor task via gross movements of the arms, hands, and fingers, as well as fine motor extremity dexterity. A higher Purdue Pegboard Test score indicates better dexterity and coordination. Scores were compared to normative data, compiled from healthy individuals, to produce a Z-score (0 being population mean). A positive Z-score indicates the raw score is higher than the mean average; a negative Z-score indicates the raw score is below the mean average.

From start of study up to 262 weeks
Number of Participants With Hyperammonemic Episodes
Tidsramme: From study start up to 262 weeks

Hyperammonemic episodes" are defined as either an AE for which an Investigator observed symptoms considered to be consistent with a "hyperammonemic episode", or an AE in a patient meeting all 3 of the following criteria: 1. Confirmed ammonia level ≥100 μM, 2. One or more symptoms related to hyperammonemia, 3. Requiring hospitalization or emergency room management.

From study start up to 262 weeks
Number of Participants With Seizures
Tidsramme: From study start up to 262 weeks
From study start up to 262 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Studieleder: Mattias Rudebeck, PhD MSc BMedSc, Immedica Pharma AB

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

7. desember 2017

Primær fullføring (Faktiske)

15. desember 2022

Studiet fullført (Faktiske)

15. desember 2022

Datoer for studieregistrering

Først innsendt

11. desember 2017

Først innsendt som oppfylte QC-kriteriene

14. desember 2017

Først lagt ut (Faktiske)

20. desember 2017

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

24. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

31. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere